机构:[1]Kunming Med Univ, Div Gastroenterol, Affiliated Hosp 1, Kunming 650031, Yunnan, Peoples R China昆明医科大学附属第一医院[2]Yunnan Kunming Blood Ctr, Transfus Med Res Dept, Kunming 650011, Yunnan, Peoples R China[3]Nankai Univ, Sch Med, Postdoctoral Res Stn, Tianjin 300071, Peoples R China[4]Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, 288 Nanjing Rd, Tianjin 300020, Peoples R China[5]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Blood Dis, Inst Hematol, 288 Nanjing Rd, Tianjin 300020, Peoples R China[6]Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, 288 Nanjing Rd, Tianjin 300020, Peoples R China[7]Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming 650031, Yunnan, Peoples R China[8]Kunming Med Univ, Div Gastroenterol, Affiliated Hosp 2, Kunming 650101, Yunnan, Peoples R China
Longitudinal studies have improved current diagnostics and management of metabolic associated fatty liver disease (MAFLD) patients by liver biopsy and therapeutic intervention, yet the deficiency of biomarker spectrum for dissecting subtypes largely hinders the symptomatic treatment. We originally enriched serum from peripheral blood of 618 healthy donors (HD) and 580 MAFLD (400 NAFL, 180 NASH) patients according to multiple clinicopathological indicators. Microarray profiling and qRT-PCR were conducted to identify lncRNAs as candidate biomarkers of MAFLD. Then, we analyzed the matching score of the indicated lncRNA with CAP or MAFLD-associated pathological parameters as well. Additionally, we took advantage of interaction network together with gene expression profiling analysis to further explore the underlying target genes of the identified lncRNA. Herein, we found CAP in nearly all of the NAFL (399/400) and NASH (179/180) patients was higher than that in the HDs (611/618). The differentially expressed lncRNAs were involved in multiple metabolic or immunologic processes by regulating MAFLD-associated pathways. Of them, serum lncPRYP4-3 was identified as a novel candidate biomarker of MAFLD, which was further confirmed by correlation analysis with clinical indicators. Thereafter, we deduced PRS4Y2 was a candidate target of lncPRYP4-3 and mediated the dysfunction in NAFL and NASH patients. Serum lncPRYP4-3 served as a novel biomarker of MAFLD and helped distinguish the subtypes and benefit precise intervention therapy. Our findings also provided overwhelming new evidence for the alteration in biological processes and gene ontology in MAFLD patients.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81660410]; Natural Science Foundation of TianjinNatural Science Foundation of Tianjin [19JCQNJC12500]; Science and Technology Project of Tianjin [17ZXSCSY00030]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2019M661033]; Natural Science Foundation of YunnanNatural Science Foundation of Yunnan Province [2017FE468-174]; Yunnan Science and Technology Project [2015HB073, CXTD201610, L-2017018, 2018NS0100]; Nanyang Science and Technology Project of Henan Province [JCQY012]; Department of Science and Technology of Shangrao City (2020); Reserve Training Project of "Thousand" Project of Health Science and Technology Talents in Kunming [2019-sw-52]; NHC Key Laboratory of Drug Addiction Medicine (Kunming Medical University)
第一作者机构:[1]Kunming Med Univ, Div Gastroenterol, Affiliated Hosp 1, Kunming 650031, Yunnan, Peoples R China
通讯作者:
通讯机构:[1]Kunming Med Univ, Div Gastroenterol, Affiliated Hosp 1, Kunming 650031, Yunnan, Peoples R China[4]Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, 288 Nanjing Rd, Tianjin 300020, Peoples R China[5]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Blood Dis, Inst Hematol, 288 Nanjing Rd, Tianjin 300020, Peoples R China[6]Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, 288 Nanjing Rd, Tianjin 300020, Peoples R China
推荐引用方式(GB/T 7714):
Yang Hongju,Li Qian,Zhang Leisheng,et al.LncPRYP4-3 serves as a novel diagnostic biomarker for dissecting subtypes of metabolic associated fatty liver disease by targeting RPS4Y2[J].CLINICAL AND EXPERIMENTAL MEDICINE.2020,20(4):587-600.doi:10.1007/s10238-020-00636-1.
APA:
Yang, Hongju,Li, Qian,Zhang, Leisheng,Zhu, Mei,Niu, Jie...&Wang, Kunhua.(2020).LncPRYP4-3 serves as a novel diagnostic biomarker for dissecting subtypes of metabolic associated fatty liver disease by targeting RPS4Y2.CLINICAL AND EXPERIMENTAL MEDICINE,20,(4)
MLA:
Yang, Hongju,et al."LncPRYP4-3 serves as a novel diagnostic biomarker for dissecting subtypes of metabolic associated fatty liver disease by targeting RPS4Y2".CLINICAL AND EXPERIMENTAL MEDICINE 20..4(2020):587-600